Lactobacillus brevis HY7401 having protective effect against colitis and products containing thereof as effective component

摘要

The present invention provides new Lactobacillus brevis ( Lactobacillus brevis has the effect of preventing the generation of colitis ) HY7401 and pharmaceutical compositions containing them as an active ingredient, a fermented milk, more particularly for beverages, and dietary supplement, Lactobacillus brevis HY7401 is a nitric oxide produced by the process of the inflammation-inducing agent of lipopolysaccharide (lipopolysaccharide) (Nitric oxide) inhibited the production of, and dextran sulfate sodium (dextran sulfate sodium) inhibiting the hydroperoxide miel oxidase (Myeloperoxidase) activity in experimental animal model of colitis induced and, inflammatory colitis, the surface of the pro-inflammatory cytokines (proinflammatory cytokine) IL-1 and IL-6 and inhibit the protein expression, for the purpose of treatment and / or prevention of the transcription factor NF-B for inhibition and inhibition factors involved in the expression of inflammatory cytokines by increasing the active colitis IB can be used as a jeongjangje, fermented food or dietary supplement.